L S CLARK - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

L S CLARK

Showing results (21-30 of 23) with videos related to

Pageof 3

Sort By:

You have reached the last page of results.This site can display upto 23 results.

Pharmacogenetics|October 19, 2000

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trialM P Murphy, M E Beaman, L S Clark, et al.

Mutagenesis|November 4, 1998

Identification and chromosomal assignment of two heterozygous mutations in the Trp53 gene in L5178Y/Tk(+/-)-3.7.2C mouse lymphoma cellsL S Clark, D W Hart, P J Vojta, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2013

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelD L Hertz, S Roy, A A Motsinger-Reif, et al.

Pageof 3

Search research articles

Showing results (21-30 of 23) with videos related to

Sort By:

Pageof 3

You have reached the last page of results.This site can display upto 23 results.

Pharmacogenetics|October 19, 2000

Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trialM P Murphy, M E Beaman, L S Clark, et al.

Mutagenesis|November 4, 1998

Identification and chromosomal assignment of two heterozygous mutations in the Trp53 gene in L5178Y/Tk(+/-)-3.7.2C mouse lymphoma cellsL S Clark, D W Hart, P J Vojta, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2013

CYP2C8*3 increases risk of neuropathy in breast cancer patients treated with paclitaxelD L Hertz, S Roy, A A Motsinger-Reif, et al.

Pageof 3